Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations
Vesicular Stomatitis Virus (VSV) has emerged as a promising candidate for various clinical applications, including vaccine development, virus pseudotyping, and gene delivery. Its broad host range, ease of propagation, and lack of pre-existing immunity in humans make it ideal for therapeutic use. VSV...
Saved in:
Main Authors: | Alaa A. Abdelmageed, Stephen Dewhurst, Maureen C. Ferran |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/17/1/16 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Oncolytic virotherapy, volume II
by: Ahmed Majeed Al-Shammari, et al.
Published: (2025-01-01) -
The replicability of oncolytic virus: Defining conditions in tumor virotherapy
by: Jianjun Paul Tian
Published: (2011-05-01) -
Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis
by: Joseph Malinzi, et al.
Published: (2018-11-01) -
The concerted actions of microRNA-29a and interferon-β modulate complete Freund's adjuvant-induced inflammatory pain by regulating the expression of type 1 interferon receptor, interferon-stimulated gene 15, and p-extracellular signal-regulated kinase
by: Chien-Cheng Liu, et al.
Published: (2025-03-01) -
HDAC6 Facilitates PRV and VSV Infection by Inhibiting Type I Interferon Production
by: Hu Zheng, et al.
Published: (2025-01-01)